Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Eligibility and Prescription Rates in Patients Presenting With Recurrent Acute Coronary Syndromes
Despite significantly higher eligibility rates, PCSK9 inhibitor uptake remains low in recurrent ACS patients, demonstrating the need to raise further awareness about eligibility criteria and encourage proactive prescription to prevent recurrent cardiovascular events.
Authors
- Shane Nanayakkara (ORCID: https://orcid.org/0000-0002-0146-6588)
- William B He (ORCID: https://orcid.org/0000-0003-0476-1109)
- Dylan Jape (ORCID: https://orcid.org/0000-0001-8309-7060)
- J. Shaw (ORCID: https://orcid.org/0000-0002-9045-9119)
Institutions
- Baker Heart and Diabetes Institute (AU)
- Alfred Health (AU)
Publication Details
- Journal
- Heart Lung and Circulation
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.hlc.2024.07.012
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.72